| Survival: | 9.0 months |
| Toxicity Grade: | 2 |
| Treatments: | Immunotherapy |
| Drugs: | Proleukin |
| Country: | United Kingdom |
| City/State/Province: | London |
| Hospital: | St. Bartholomew’s Hospital |
| Journal: | Link |
| Date: | 1/2001 |
| Description: |
| Patients: This Phase II study involved 29 patients with malignant pleural mesothelioma. None of these patients had been administered previous chemotherapy or immunotherapy. Treatment: The treatment consisted of the administration of human recombinant Interleukin-2. Toxicity: Toxicities included fever (grade 2), cutaneous toxicity, nausea and vomiting (grade 1), and chest pains. Results: Overall median survival was 9 months from the date of first treatment. Support: The cost of the interleukin-2 was subsidized by Chiron UK Limited. Chiron manufactures interleukin-2 (Proleukin). Correspondence: R.M. Rudd, MD |